The anticonvulsant effect of 17AAG in a TLE mouse model. (A) Experimental design. (B) Example of daily recording of SRSs in the 17AAG group. (C and D) Statistical analysis of the number of seizures per day and seizure-free days. Cumulative data from four individual experiments with 18 mice in the DMSO group and 21 mice in the 17AAG group pooled per experiment (***, P < 0.001, Mann–Whitney test or Student’s t test). (E) Number of seizures per day and percentage of seizure-free days in the first 10 mice of the 17AAG and DMSO groups, respectively. The average fold change in seizure frequency in individual mice before and after administration was 0.23 ± 0.02 (0.44–0.06) in the 17AAG group (n = 21) and 1.49 ± 0.09 (2.45–0.83) in the DMSO group (n = 18). (F) Representative 1-min EEG tracings recorded from mice during the preinjection baseline and during drug injection in the 17AAG and DMSO groups, respectively. Statistical analysis of interictal spikes from two mice in each group are presented (***, P < 0.001, Student’s t test). (G) Representative images of GFAP staining in the sclerotic hippocampus and statistical analysis (Normal, n = 6; DMSO, n = 8; 17AAG, n = 8, ***, P < 0.001, one-way ANOVA, post hoc Tukey's test). Data are from two individual experiments (G). Bars: (top) 100 µm; (bottom) 30 µm. Data are representative of two (G) independent experiments.